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LPS, a cell wall component of all Gram-negative bacteria, is well known to be
responsible for a large part of the toxic manifestations associated with infections by
such bacteria.When administered to experimental animals, LPSinduces pathophysio-
logicchanges that vary with the experimental conditions . A generalized andpoten-
tially lethal inflammatory reaction, knownas the generalized Shwartzman reaction,
can be elicited in several animal species, especially in rabbits (1), but also in mice
(2). Typically, the reaction requires two consecutive, relatively low doses ofLPS and
is clinically manifested as a shocksyndrome . The occurrence ofthe syndrome always
requires careful dosage and timing (2). This reaction is of particular interest, since
it shares pathogenetic elements with septic shock in humans, acondition that occurs
with increasing frequency, and is a major cause of death among hospitalized pa-
tients in intensive care units .
Evidence from many studies indicates that the complexpathogenesis of septic shock
and of the LPS-induced reactions is orchestrated by a complex network of endoge-
nous mediators, whose release is triggered by the interaction of LPS with various
cell types, especially phagocytes and endothelial cells . In recent years one particular
group of mediators, the cytokines, has elicited considerable interest for their role
in the LPS-induced inflammatory responses. Direct as well as indirect observations
indicate that TNFa andIL-1, two cytokines mainly produced by macrophages/mono-
cytes, maybe theprincipal mediators ofthe endotoxin-induced lethality . Thus, both
these cytokines are released into the blood stream in humans (3, 4) or animals (3,
5) after intentional exposure to endotoxin, as well as during septic shock or menin-
gococcal infection in patients (6-8) . Furthermore, TNF induces profound shock,
tissue injury, and death when infused into experimental animals (9-13) . Moreover,
a very strong synergism between TNF and bacteria or their products in causing
ageneralized Shwartzman-like reaction has been observed (14, 15). Finally, lethality
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induced by LPS or Gram-negative bacteria can be inhibited by passive immuniza-
tion with antiTNFa antibodies (9, 16, 17) . Recently, it has also been demonstrated
that IL-1 can markedly potentiate the lethal effect of recombinantTNFa in mice
(18, 19) .
Nevertheless, TNFa and IL-1 are certainly not the only major cytokines medi-
ating septic shock. Additional factors seem to be IFN--y and IL-6 . IFN- ,y is the prin-
cipal macrophage activating factor released by activated T cells (20, 21) . That it is
involved in the pathogenesis of the inflammatory responses to LPS became evident
from in vivo studies done in our laboratory, which demonstrate that local as well
as generalized and lethal Shwartzman reactions elicited in mice can be completely
prevented by pretreatment of the animals with mAb to IFN-,y (2, 22) .
The studies reported in the present paper were done to gain more insight into
the role ofIFN-,y in the pathogenesis ofthe generalized Shwartzman reaction, and
in particular to analyze its interaction with other cytokines, namely TNFa, IL-6,
and IFN-a and/or -ß .
Materials and Methods
Mice.
￿
All experiments, unless otherwise stated, were done on female 7-8-wk-old NMRI
mice bred under nonspecific pathogen-free (SPF) 1 conditions (Experimental Animal Breed-
ing Facility, University of Leuven) .
Reagents.
￿
Phenol-extracted LPS from Serratia marcescens was purchased from Sigma Chemical
Co. (St . Louis,MO ; Cat. no . L6136, lot 9384019) . LPS derived from Escherichia coli (0111.B4)
was purchased from Difco Laboratories (Detroit, MI) . Stock solutions were prepared and
diluted in PBS, pH 7.4 . n-Galactosamine-hydrochloride was purchased from Janssen Bio-
chimica (Beerse, Belgium) .
Cytokine Preparations.
￿
Mouse IFN-a,ß (MuIFN-a,ß) was prepared on L929 cells infected
with Newcastle disease virus (Komarov strain), concentrated, and partially purified by frac-
tional precipitation withammonium sulfate (23) . The specific activity of the preparation used
was 106,8 U/mg protein . Recombinant murine IFN-al (rMuIFN-al) was derived from CHO-
psV10EF3 cells (24), kindly provided by Dr. J . Trapman (Erasmus University, Rotterdam,
The Netherlands). The interferon was purified by affinity chromatography on goat polyclonal
antibodies against MuIFN-a,ß giving preparations with a specific activity of ti10" (range :
106''-108 '5) U/mg protein . Recombinant murine IFN-Q (rMuIFN-ß) was derived from CHO-
flAA3 cells, also kindly provided by Dr. J . Trapman . The interferon was purified by affinity
chromatography on monoclonal anti-IFN-ß (25), giving a preparation of "1083 (range :
10'' 9-10 8 '8) U/mg protein . rMuIFN--y was derived from the supernatant fluid of Mick cells,
aCHO cell line that carries and expresses an amplified murine IFN - 'YcDNA (26) . This inter-
feron was purified by affinity chromatography on the F3 mAb to a specific activity of N10''
(range : 1065-108 -°) U/mg protein. Dilutions of the cytokines were made in pyrogen-free
saline .
Antibodies.
￿
mAbs againstMuIFN-y were obtained as ascites fluid from thymusless nude
mice (nu/nu) inoculated with the (rat x mouse) hybridoma lines F1 and F3 . The potential
of both antibodies to bind IFN-,y and to neutralize its antiviral activity and macrophage-
activating effect are described elsewhere (22, 27). The neutralizing potential of the Fl and
F3 antibodies were 10-2
.5 and 10-s . í against 30 U/ml of MuIFN - 1', respectively (IgG con-
tent : F3, 2.5 mg/ml ; Fl, 5.3 mg/ml) . Purified F3 mAbs (neutralizing titer of 10-5 '' against
30 U/ml) were obtained by affinity chromatography on an anti-rat K chainmAb (MARK-1,
reference 28) . A mouse mAb against rat IFN-y with binding and neutralizing activity for
rat IFN-,y as well as MuIFN-y (DB-1 cell line obtained by courtesy ofDr. Schellekens, TNO,
Rijswijk, Netherlands) (29) was obtained as ascites fluid from BALB/c mice (neutralizing
potential : 10-35 against 6 U/ml ofrat IFN-y; 10-2
.5 against 30 U/ml of mouse IFN-y) . Con-
trol ascites fluid was obtained from nude mice injected with a rat x mouse hybridoma thatHEREMANS ET AL.
￿
1855
produces small amounts of irrelevant Ig (IgG content: 0.026 mg/ml; neutralizing titer of
<10-1.5 against 30 U/ml murine IFN-oc, IFN-ß, and IFN-7). For administration in mice, all
antibodies were diluted in pyrogen-free saline.
InductionofGeneralizedShwartzmanReaction.
￿
The generalized Shwartzman reaction in mice
was elicited by two consecutive injections of S. marcescens LPS: a preparatory one given in
varying dose in the footpad followed after 24 h by a standard provoking doseof 100 lag intra-
venously. The occurrenceof the generalized Shwartzman reaction was evaluated by morbidity
scores and by mortality rates.
AssaysforBiological Activity.
￿
Blood samples for determination on sera were taken from the
orbital sinus and were allowed to clot at room temperature for about 1 h and at VC over-
night. Serum samples were clarified and stored at -70'C until titration.
Interferon was titrated on primary mouse embryo fibroblasts (MEF)using a standard CPE
inhibition assay with mengovirus as a challenge (23). Interferon activity was expressed in
units per milliliter in terms of the NIH standard preparation G002-904-511. The presence
of TNF did not interfere in the assay.
TNF levels in sera were determined using a cytotoxic assay on L929 cells as described
(30). Briefly, serial dilutions (50 ul/well)of the serum samples were made in duplicate in 96-
well microtiter plates (Nunc, Roskilde, Denmark) in EMEM supplemented with 2.2 g/liter
sodium bicarbonate and 1017o heat-inactivated FCS (Gibco Europe, Paisley, Scotland). To
each well 100 pl of L929 cells (400,000/ml) in exponential growth were added in complete
medium containing 2 Rg/ml actinomycin D. After 18-24 h of incubation at 37'C the sur-
viving cells were fixed and stained with 0.5% crystal violet (Merck) and the absorbance was
measured in a Titertek at 590 nm. rMuTNFa (Innogenetics, Gent, Belgium ; sp act 4 x
107 U/mg protein) was included as a standard. The numberof units/milliliter ofactivity was
defined as the reciprocal of the dilution required to induce 50% decrease in absorbancerela-
tive to control cells exposed to actinomycin alone. The detection limit ofthe assay was 50-100
pg rTNFct/ml serum. In some experiments a polyclonal rabbit antiserum directed against
TNFa (Innogenetics, Ghent, Belgium) was added to test the specificity of the toxicity.
IL-6 assays were done as described in Van Snick et al. (31) by incubating 2 x 103 IL-6-
dependenthybridoma cells (mouse-mouse hybrid 7TD1) with serial dilutionsofthe test samples.
After 4 d, viability was measured in a colorimetric assay with hexosaminidase. IL-6 concen-
trations (loglo units/ml) were calculated from titration endpoints. 1 U of IL-6 was defined
as the amount required to obtain half-maximal growth of the cells. Pure natural IL-6 was
included as an internal standard. The detection limit of the assay was 1-10 pg/ml.
TestforEndotoxin Contamination.
￿
Batches of IFN-.y and anti-IFN-.y antibodies were tested
for endotoxin content by a chromogenic Limulusamoebocyte lysate assay (KabiVitrum, Stock
holm, Sweden) and not used for in vivo experiments unless they contained <2 ng/ml.
Statistical Methods.
￿
Statistical methods were those used in a previous study (32).
Results
Inductionofthe Generalized Shwartzman Reaction in Mice. Suboptimal, Optimal, andSupraop-
timalInduction Schedules. Groups of4-6 mice were given two consecutive injections
of S marcescens LPS: a varying preparatory dose, followed after 24 h by a standard
100 Ag provocative dose, the latter always given intravenously. The development of
overt disease symptoms was then monitored over a period of 48-72 h. Table I shows
that, depending on the route and size of the preparatory dose, the mice were sensi-
tized towards the disease-inducing potential of the provocative dose. The symptoms
consisted of pilo-erection (= disease score 0), lethargy, diarrhea, serous or hemor-
rhagic conjunctivitis (score 1), hemorrhagic lesions on ears and/or extremities (score
2), paralysis (score 3), and death (score 4).
Ofvarious schedules tested, the optimal one was found to consist of a preparatory
5 Ag dose in the footpad combined with a provocative 100 wg intravenous dose. At-1856
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TABLE I
Incidence and Severity of Shock (Generalized Shwartzman Reaction) in Mice
Given different LPS Treatment Schedules
The generalized Shwartzman reaction was elicited in mice by two consecutive
S . marcescens LPS injections, the preparatory one (varying dose and route as
indicated) followed after 24 h by a standard 100 kg i .v . provoking dose .
' Figures represent means ofaverage disease scores over n groups ofmice (4-6
mice/group) .
tempts to sensitize mice by intravenous or intraperitoneal rather than intra-footpad
doses were unsuccessful . Preparatory doses smallerthan theoptimal5wg ledto lesser
disease symptoms and mortality; this will further be referred to as the suboptimal
induction schedule. Preparatory doses higher than the optimal 5 l~g also failed to
sensitize the mice ; this will further be referred to as the supra-optimal induction
schedule . The ability of a 5 jig footpad dose to sensitize the micewasalso abrogated
by simultaneous intravenous injection ofan additional 10 ug dose (Exp . 3 ofTable I) .
Cytokine Levels in the Serum of Mice with Generalized Shwartzman Reaction .
￿
In view
ofthe apparent role ofendogenous cytokines in the pathogenesis of the generalized
Shwartzman reaction, it is of interest to know to what extent these cytokines are
detectable in the general circulation . Therefore, blood samplestakenfrom mice given
the standard, suboptimal, or supraoptimal Shwartzman induction schedules were
titrated for the presence of IFN, IL-6, and TNF .
Fig. 1 shows the course ofserumIFN levels, as detected by antiviral effect on pri-
Exp .
Preparatory
Route
LPS dose
Wg
Mean
disease
score (n)'
Mortality
Dead/total Percent
1 Footpad 0 0 .2 (4) 0/17 0
0 .5 1 .2 (4) 0/19 0
1 .0 1 .7 (1) 1/6 17
5 .0 3.5 (8) 32/38 84
25 2.0 (4) 6/18 33
50 1 .0 (1) 1/4 25
2 Footpad 5 3.25 (1) 3/4 75
i .v . 0.01 0.0 (1) 0/4 0
0 .1 0.0 (1) 0/4 0
0 .5 0.0 (1) 0/4 0
1.0 1 .4 (2) 2/8 25
5.0 0 .5 (1) 0/4 0
10 .0 0.0 (1) 0/4 0
i .p . 0.01 1 .5 (1) 0/4 0
0 .1 0 .5 (1) 0/4 0
0 .5 0.25 (1) 0/4 0
1 .0 0.0 (1) 0/4 0
5 .0 0.5 (1) 0/4 0
10 .0 0.25 (1) 0/4 0
3 Footpad 5 .0 3.13 (6) 28/38 (74)
i .v . 10 0.3 (5) 1/32 (3)
Footpad 5.0 0.47 (6) 1/39 (3)
+ i .v . 10.0HEREMANS ET AL .
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FIGURE 1 . Course of serum
IFN levels in mice given stan-
dard and supraoptimal Shwartz-
man induction schedules. All
mice received a standard pro-
voking dose of 100 FIg S . ma :-
cescens LPS i.v . and varying
preparatory doses in the foot-
pad : (A) none ; (B) optimal dose
of 5 kg; (C) supraoptimal dose
of50 jig . (O) control mice ; (")
anti-IFN-.y antibody treatment
(F3 ascites, 0.1 ml i.p .) 24 hbe-
fore the preparatoryLPS dose .
The sign + in panel B indi-
cates time point at whichmost
mice have died .
mary mouse embryo fibroblasts . As can be seen in Fig. 1, the preparatory dose of
LPS (5 or 50 lAg in the footpad) did not itself result in detectable circulating IFN.
The provoking dose (100 Wg i.v) induced high circulating IFN levels in about half
ofthe mice that had not received any preparatory dose (panel A) . In mice that had
received an optimal preparatory dose (5 FAg), the levels were similar, but persisted
for a longer time (panel B, open symbols) . Finally, in mice whichhadreceived a supraop-
timal (50 Nzg) preparatory dose, the provoking dose failed to induce IFN (panel C) .
Similarly, in mice pretreated with anti-IFN-,yantibody, serumIFN remained unde-
tectable (panel B, filled symbols) .
The interferon-like antiviral activity measured was completely neutralizable by
antiserum against IFN-a/(3, but notby antibodies against IFN-y or toTNFa (neu-
tralization data not shown) . Although this indicates that the antiviral activity was
predominantly due to IFN-a/(3 and not toTNFa (alone or in synergy with IFN-
a/S), the presence of a minor fraction of IFN-y cannot be excluded .
CirculatingTNF levels are shown in Fig. 2 . TNF levels were detectable only at1858
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a time point 2 h after injections ofLPS. The 100 Ag ix . LPS injection inducedTNF
levels that were equally high, whether or not the mice had received the standard
Shwartzman-preparatory LPS dose of 5 p .g that is necessary for lethality to occur
(panelsA and B, open symbols) . However, when the preparatory dose was supraop-
timal (50 p,g) so that thereaction wasnot lethal,TNFlevels werelowor undetectable
(panel C) . Also, in mice pretreated with anti-IFN- ,y antibody, TNF remained unde-
tectable (panel B, filled symbols). Cytotoxic activity in the serum was completely neu-
tralizable by a polyclonal antiTNF antibody (neutralization data not shown) .
Circulating IL-6 levels in the generalized Shwartzman reaction are tabulated in
Table II . As can be seen, little ifanydifference was found in the levels between mice
given suboptimal, optimal, or supraoptimal induction schedules . Also, induction
of IL-6 by a second dose ofLPS was not subject to hyporeactivity as is the case for
induction of IFN-'Y or TNF-a (see Figs . 1 and 2) . Furthermore, protection of the
FIGURE 2 . Course of TNF
levels in sera ofmice given stan-
dard and supraoptimal Shwartz-
man induction schedules. All
mice received a standard pro-
voking dose of 100 wg S . mar-
cescens LPS i.v. and varying
preparatory doses in the foot-
pad : (A) none ; (B) optimal dose
of 5 Iwg ; (C) supraoptimal dose
of 50 Wg.(O) control mice; (")
anti-IFN-.y antibody treatment
(F3 ascites, 0.1 ml i.p.) 24 h be-
fore the preparatoryLPSdose .4.0
0.0
TABLE II
IL-6 Levels in Serum ofMice Given LPS Injections to Induce Generalized Shwartzman
Reaction : Protective Regimens Are Not Associated with Lower IL-6 Levels
IL-6 levels in serum at times (h) :
Treatment
￿
(log(o units/ml, mean t SE)
The generalized Shwartzman reaction was elicited in mice by two consecutive S. marcescens
LPS injections, the preparatory one (varying dose as indicated) followed after24 h by a standard
100 Wg i .v . provoking dose .
" mAb F3, ascites fluid, 0 .1 ml i.p . 24 h before preparatory LPS dose .
t n, Number of independent serum samples tested .
mice by pretreatment with anti-IFN--y antibody was not associated with lower levels
of IL-6 .
In conclusion, in comparisons of various lethal andnonlethal Shwartzman induc-
tion schedules, there seemed to be a rather good correlation between lethality and
IFN or TNF levels and no correlation between lethality and IL-6 levels .
Protection of Mice Against the Generalized Shwartzman Reaction by Anti-IFN-y Anti-
body. Theinvolvement ofIFN-yin the pathogenesis ofthegeneralized Shwartzman
reaction was also studiedby testing the effects of neutralizing anticytokine antibodies
on the course of the disease . Fig . 3 shows the results of a series of experiments in
which groups ofmice were given an intraperitoneal injection of three different anti-
IFN-y mAb preparations, 24 h before the preparatory LPS dose of the standard
Shwartzman induction schedule. Allthree monoclonals tested were found to be effective
m 3.0 ~no
N
m h
m 2.0 _
HEREMANS ET AL .
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FIGURE 3 .
￿
Prevention ofgen-
eralized Shwartzman reaction in
mice by treatment with anti-
IFN- ,y antibodies (dose-re-
sponse curve). The reaction was
elicited in mice bytwo consecu-
tive S . marcescens LPS injections,
a preparatory one (5 kg in the
footpad) followed after 24 h by
a provoking one of 100 lAg ix .
(" ) control; (A) Fl ascites ; (O)
F3 ascites ; (C]) DB1 ascites. An-
tibodies were given (0 .1 ml i .p .)
24 h before the preparatory LPS
dose . In parentheses number of
experiments(4 mice per group)
over which average disease scores
are calculated .
Shwartzman induction-
Prep . LPS Dose (ug)
Anti-IFN- .y
antibody" 2 24 26
5 (n = 15)t - 2.88 ( t 0.07) 1 .78 (t 0.05) 4.21 ( t 0.08)
5 (n = 15) + 2.63 ( t 0.09) 1 .22 (t 0.08) 3.92 ( t 0.10)
0.5 (n = 4) - 2.75 ( t 0.06) 1 .22 (t 0.17) 4.42 ( t 0.10)
50 (n = 7) - 3.88 ( t 0.06) 2.10 (t 0.14) 3.98 (t 0.07)
50 (n = 3) + 3.80 ( t 0.11) 1 .63 (t 0.17) 3.67 (t 0.03)
0 (n = 8) - 4.10 (t 0.15)1860
￿
INTERFERON .y IN LPS-INDUCED SHOCK REACTIONS
in protecting the mice against the syndrome . mAb Fl, which was the least effective
is also known to be poorly neutralizing for IFN-,y in vitro (22) .
Additional informationon the protective effects of anti-IFN-y antibodies is given
in Table III . It can be seen that highly purified anti-IFN-y antibody, F3, yielded
protection similar to that provided by unpurified ascites fluid . Furthermore, protec-
tion afforded by a single injection of anti-IFN-y antibody can be seen to last for
more than 7 d .
Enhancing Effect ofExogenous IFN-yon the Development of GeneralizedShwartzman Reac-
tion . From the resultsoftheexperimentswith anti-IFN-y antibody it was hypothe-
sized that the sensitizing effect of a preparatory LPS dose in the generalized
Shwartzman reaction was mediated by IFN- ,y induced by that dose. We therefore
tested the ability of IFN- ,y itself to prepare mice for alethal Shwartzman reaction .
To that end intraperitoneal injections of rMuIFN-y were added to the suboptimal
Shwartzman induction schedule. These injections were given 2 h after the prepara-
tory LPS dose . Table IV shows the results of these experiments . It can be seen that
IFN-,ytreatment did indeed enhance the sensitivity of mice to the Shwartzman reac-
tion, irrespective of whether it was given alone or in association with a suboptimal
preparatory LPS dose . The effect was dose dependent, a minimal dose of 104-'-1050
U being required for the appearance of symptoms and 105 .1 U being required for
lethality .
A time-response experiment (Table V) showed that IFN- ,y was able to exert its
sensitizing effect if it wasgiven before thepreparatory dose or between the prepara-
tory andprovocative LPS injections . It was found ineffective if given 2 h after the
provocative dose .
Protective Effect of IFN-otlO towards Generalized Shwartzman Reactions in Mice.
￿
LPS
TABLE III
Effect of Treatment with Different Anti-IFN-y Antibody Preparations
on the Severity and Mortality Rate of the Generalized
Shwartzman Reaction Induced in Mice
The generalized Shwartzman reaction was elicited in mice by two consecutive
S. marcescens LPS injections, a preparatory one (5 ftg in the footpad) followed
after 24 h by a provoking one of 100 ug i.v .
' For origin and specificity, see Materials and Methods . Doses were as follows :
F3 - asc : 5.6 loglo neutralizing units (NU) = 250 l+g IgG ; F3 - pure : 6.2
loglo NU = 200 Wg IgG ; F1 - asc : 3 .3 loglo NU = 530 Wg IgG ; DB1 -
asc : 3 .3 loglo NU = 400 i4g IgG .
1 Number of groups (4-6 mice per group) over which average disease scores
are calculated .
Antibody'
Preparations Time n$
Average
disease
score Mortality Percent
IFN- ,y (F3 - asc) Day - 1 8 0.65 2/37 5
IFN- ,y (F3 - asc) Day - 7 1 0 0/6 0
IFN-'Y (F3 - pure) Day - 1 1 0 0/4 0
IFN--y (Fl - asc) Day - 1 9 1 .27 6/41 15
IFN--y (DB1 - asc) Day - 1 3 0.15 0/13 0
Saline 19 3 .5 75/92 82HEREMANS ET AL .
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TABLE IV
Enhancing Effect of Systemically Administered IFN-y on Development of
LPS-induced Shock in the Generalized Shwartzman Reaction
Shwartzman
induction
schedule
The generalized Shwartzman reaction was elicited in mice by two consecutive
S . marcescens LPS injections, the preparatory one (varying dose as indicated)
followed after 24 h by a standard 100 Isg i .v . provoking dose .
" Intraperitoneally at time + 2 h relative to time of preparatory LPS injection .
t Number of experiments (each with groups of 4-6 mice) over which data are
pooled .
S Value in log rank of nul hypothesis for difference in score distributions be-
tween treated and "nil" groups .
induces various otherCyokines, including IFN-a/(3 (see Fig . 1) . Therefore, we wanted
to test the effect of IFN-a//3 on the occurrence ofthe Shwartzman reaction . Prelimi-
nary experiments having indicated that anti-IFN-a//3 antibody failed to affect the
reaction (data not shown), we tested the effect of IFN-a/(3 administered intraperi-
toneally at various time points in mice that were given the standard Shwartzman
induction schedule . Table VI reveals a protective effect ofa high dose (10" U/ml)
ofnatural IFN-a/(3, given 2 h afterthe preparatorydose ofLPS. TableVI also shows
that the observation was confirmed with recombinant MuIFN-cal, but not with
recombinant MuIFN-(3 .
Inability of Small Doses ofLPS to Minnick the Protective Efects of Cytokines or Anticyto-
kines. The experimentsdescribed in this paragraph were done to eliminatethepos-
sibility that the protective effects of anti-IFN-y or the sensitizing effect of IFN-'Y
weredue to contamination of theinjected preparations with small amounts ofLPS.
Optimal as well as suboptimal inductionschedules were used ; twoLPS preparations
were taken as prototypes for possible contaminants (E. coli and S . marcescens) ; two
doses were selected as being representative forpossible contaminants (0.2 and 2 ng
per injection) ; two injection times were selected, namely those at which prepara-
tions ofanti-IFN-y antibodyand ofIFN-y hadbeen foundto provide in vivo effects.
Table VII showsthat undernone ofthese circumstanceswas thereanyevidence that
LPS injections mimick the effects of IFN-y or of anti-IFN-y antibody.
(preparatory
dose of
LPS, 14g)
Dose" of
IFN-.y
(logto U/ml) n t
Average
disease score
(p value)s
Mortality
Dead/total
number
Percent
5 5 .7 2 3.62 (0.3) 7/8 88
Nil 3.20 10/15 67
0 .5 5 .7 4 3 .43 (10-e .t ) 18/23 78
Nil 0 .74 0/23 0
0 5 .7 2 2 .55 (10-4.E ) 4/9 44
Nil 0.30 0/10 0
0 .5 5 .7 1 2 .80 (0.009) 3/6 50
5.0 1 .67 (0.009) 0/6 0
4 .7 1 .83 (0.009) 0/6 0
4.0 1 .00 (0.18) 0/6 0
Nil 0.50 0/6 01862
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TABLE V
Enhancing Effect ofSystemically Administered IFN-y on Development of
LPS-induced Shock in the Generalized Shwartzman Reaction :
Time-Response Relationship
The generalized Shwartzman reaction was elicited in mice by two consecu-
tive S. marcescens LPS injections, the preparatory one (suboptimal, 0 .5 !+g) fol-
lowed after 24 h by a standard 100 /tg i .v . provoking dose .
* Relative to time of preparative LPS dose .
Protection ofMice by Anti-IFN-y Antibody against a Single Lethal LPS Dose; Failure to
Protect Mice against Combined LPS + D-Galactosamine Treatment . Mice can be sensi-
tized to the lethal effects ofLPS not only by preparatory LPS injections, but also
with different microorganisms and chemical agents (33) among which is D-galacto-
samine, ahepatotoxicagent, which specifically blocks hepaticRNAsynthesisby deple-
tion offreeUTP (34) . Itwasof interest toknow whetheranti-IFN-y antibody would
be able to protect mice sensitized to LPS by this drug .
To define suitable LPS doses for this type of experiment, we determined the LD50
TABLE VI
Inhibitory Effect of Type IIFN (Natural a/,6, Recombinant a1,
or Recombinant ,B) on Severity of the Shwartzman Reaction
The generalized Shwartzman reaction was elicited in mice by two consecutive
S . marcescens LPS injections, a preparatory one (5 kg in the footpad) followed
after 24 h by a provoking one of 100 1Ag i.v .
* Number of independent experiments, each with 5-9 mice per treatment group.
Mean of average disease scores over n experiments .
s Value in log rank of null hypothesis for difference in score distributions be-
tween treated and untreated groups .
II X2 test (X2 = sum, based on n degrees of freedom, of X2 values obtained for
separate experiments) .
IFN treatment consisted of a single i.p . injection given 2 h after the prepara-
tory LPS dose . Dose of natural IFN-a/,8 : 105 .7 ; recombinant IFN-al : 1052 ;
recombinant S : 1053 U .
IFN type n*
Disease
Scorel p Values Score
Mortality
(%) p ValueH
a/S 7 Untreated 3.58 - 39/45 (87) -
Treatedl 2.45 10-9.1 20/42 (48) 0.009
a1 (rec .) 3 Untreated 3.43 - 12/17 (71) -
Treated 1 .58 10-8 .25 5/20 (25) 0.001
11 (rec .) 3 Untreated 2 .89 - 11/19 (58) -
Treated 2 .91 NS 13/19 (68) NS
Time* (h) of
IFN-y injection
(105 .1 U i.p .)
Average
disease score
Mortality
Dead/total
number
Percent
- 2 2.67 6/12 50
+ 2 3.50 10/12 83
+22 2.83 3/6 50
+26 1 .16 0/6 0
Saline 0.83 0/12 0HEREMANS ET AL .
TABLE VII
Failure of LPS to Mimick Protective Effects of Cytokines or Anti-Cytokines
against LPS-induced Shock in the Shwartzman Reaction
The generalized Shwartzman reaction was elicited in mice by two consecutive
S . marcescens LPS injections, the preparatory one (varying dose as indicated)
followed after 24 h by a standard 100 pg i.v . provoking dose .
* Given i.p . at indicated times, relative to time of preparatory LPS dose .
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ofE . coli and ofS marcescens LPS in control and D-galactosamine-treated SPFNMRI
mice. In accordance with reported findings (34, 35), simultaneous intravenous in-
jection ofmice with LPS and 20 mg D-galactosamine reduced the LD50 ofLPS 75-
to 330-fold (from 300 to 4 Ag/mouse and from 233 to 0.7 Ag/mouse forS . marcescens
andE. coli, respectively) . Next we tested the ability of anti-IFN-y antibody to pro-
tect normal or D-galactosamine-sensitized mice . As canbe seen in Table VIII, anti-
IFN-y antibody indeed provided near complete protection against a lethal dose (2
TABLE VIII
Effects of Pretreatment with Anti-IFN-y Antibody on Morbidity and
Mortality of Normal and D-Galactosamine-sensitized Mice, Given Lethal
or Sublethal Intravenous Doses of LPS
* 20 mg given intravenously, simultaneously with the provocative LPS dose .
Pretreatments given 24 h before provocative LPS injection .
s mAb F3, ascites fluid, 0 .1 ml i.p .
Exp .
Preparatory
LPS dose
(Rg)
Additional
Species
LPS*
Time (h)
injected
Dose (ng)
Average
disease
score
Mortality
(dead/total)
1 5 S. marcescens -24 1 2 .50 2/4
0 .2 3.75 3/4
0 3 .00 3/4
0 .5 + 2 2 1 .00 0/4
0 .2 0.75 0/4
0 1 .00 0/4
2 5 E. coli -24 1 3.20 3/4
0.2 4.00 4/4
0 3.25 3/4
0 .5 + 2 2 1 .25 0/4
0 .2 1 .25 1/4
0 0.75 0/4
Provocative
intravenous LPS dose
Species Ag D-galactosamine*
Disease scores (and mortality)
in mice pretreatedt with :
Saline Anti-IFN-.ys
S. marcescens 600 - 4.0(6/6) 1.0(0/6)
100 + 2.2 (2/5) 3.0 (3/5)
10 + 0.4 (0/5) 1.0 (1/5)
E. coli 500 - 4.0 (6/6) 1.0(1/6)
1 + 2.4 (3/5) 2.0 (2/5)
0 .1 + 1.6(2/3) 1.6(2/5)1864
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LD5o) of either toxin . However, it failed to affect morbidity or mortality in mice
treated with the combination of D-galactosamine and LPS.
Discussion
In this study we have analyzed the involvement of several cytokines, especially
of IFN-y, in the generalized toxic effects of LPS in mice. Mice are known to be
relatively resistant to induction of lethal shock by LPS: in our study the LD5o of
E . coli and S . marcescens endotoxins amounted to 233 and 300FAg/mouse, respectively .
However, we have previously reported (2) and we confirm here that NMRI mice
can be sensitized to the toxic effect ofLPS by a small preparatory LPS dose (5 wg)
given in thefootpad 24hbefore the intravenousprovokativedose (100 lAg) . A 75-85%
lethal shock-like syndrome is observed in such mice . Both the induction procedure
and symptoms of this syndrome resemble those of thegeneralized Shwartzman reac-
tion, as it has been described to occur in other animal species, particularly rabbits
(1) . We have therefore adopted the same term to denote the syndrome in mice.
Whereas a small local LPS dose (e.g., 5 ug) resulted in sensitization of the mice
to a subsequent intravenous LPS challenge, a higher dose (e.g., 50 jig) did not have
such an effect. One possible explanation for this biphasic response pattern is that,
a high local doses, LPS may enter the circulation in sufficient quantities to cause
a state of generalized hyporeactivity, as has been described in many reports (35) .
This interpretation gains support from the fact that the sensitizing effect of a local
LPS dose could be undone by simultaneous intravenousinjection ofa relatively small
LPSdose . Furthermore, in themice receivinga supraoptimal preparatorydose, sub-
sequent induction of circulating TNF and IFN-a/S was impaired (see below) .
We also have used another known procedure forsensitization ofmice to LPS, which
consists in treatment with D-galactosamine (34) : its simultaneous intravenous ad-
ministration withE . coli or S . marcescens endotoxins reduced the LD5o of these toxins
330- or 75-fold, respectively. Theinvolvement ofIFN-y in these lethal reactions was
studied by different approaches . Pretreatment of the mice with a single dose of a
neutralizingmAb against IFN-y prevented disease and death in mice givena single
lethal LPS dose as well as in those given the generalized Shwartzman induction
schedule . We interpret this to mean that IFN-y is produced after LPS administra-
tion, and that this IFN-y plays acrucial role in the pathogenesis of the lethal events
followingsuch injection . We also found that exogenous administration of IFN-'y by
itself or in association with a small, local dose of LPS sensitizes the mice for the
lethal effects of an intravenous challenge dose of LPS.
In contrast to mice given one lethal LPS dose, D-galactosamine-sensitized mice
were not protected against LPS by pretreatment with anti-IFN-y antibody, suggesting
that in this case, the pathogenesis of lethal LPS-induced disease may be different
and less (or perhaps not at all) dependent on the production of IFN-y .
Circulating interferon-like antiviral activity was detectable in two-thirds of the
mice given the generalized Shwartzman reaction schedule . However, this activity
was identified as IFN-a//3 rather than IFN-y . Mice that failed to develop the reac-
tion because they had notreceived thepreparatorysensitizingLPS dose, had slightly
lower IFN levels ; mice that failed to develop the reaction becausethey had received
a supraoptimal preparatory dose of LPS, or because they had received anti-IFN-y
antibody, produced no detectable circulating interferon .HEREMANS ET AL.
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To answer the question whether this IFN-cdo would have a positive or negative
influence on the development of the lethal syndrome, we studied the influence of
large doses of exogenous IFN-a/a on the development of the Shwartzman reaction .
The natural IFN-a/o mixture as well as recombinant IFN-al, but not recombinant
IFN-(3, were found to inhibit the reaction and to reduce mortality. This suggests
that systemic IFN-a, produced in association with thegeneralizedShwartzman reac-
tion, acts as a mitigating factor on the syndrome .
Otherinvestigators have provided evidence indicating that the cytokine which oc-
cupies acentral place in thepathogenesis of LPS-induced shock reactions in rodents
(9, 10), baboons (3, 16), andman (4, 6-8) is TNF . Another cytokine which has been
incriminated in shock reactionsdue to Gram-negative sepsis is IL-6 (8, 36-38). There-
fore we considered it essential to obtain information on the role of these cytokines
in ourmodel . Blood levels ofTNF paralleled those of IFN-alai: TNF was detected
in mice programmed to die from a generalized Shwartzman reaction, but not in
those protected by a supraoptimal preparatory dose of LPS or by anti-IFN-y anti-
body . This close associationbetweenTNFlevels and lethality, also observed inhumans
with Gram-negative septicemia (6-8), is consistent with an important role forTNF
in the pathogenesis ofthe syndrome . From the evidence obtained with other model
systems (5, 10-13, 39, 40) it appears most likely that TNF is atriggering factor respon-
sible for much of the pathophysiological effects of LPS .
Blood levels of IL-6, in contrast to those of TNF and IFN-ado did not correlate
with severity of the shock syndrome : LPS induced high levels of IL-6 in all cases
and kinetics were not different, whether the mice were programmed to develop a
lethal syndrome or to be protected . Thesedata arenotconfirming studies indicating
an association betweenhigh serum levels of IL-6 and fataloutcome in patients with
septic shock (8, 37). So far evidence is lacking for assigning a positive or negative
role to IL-6 in LPSpathology. Perhaps its most important role consists in stimulating
theimmune response and in inducing hepatocytes to produce acute-phase reactants
(41) .
Our study indicates that endogenous IFN-y plays a crucial role in the pathogen-
esis of lethal reactions to LPS. This raises several questions as to the substances,
cells, and interactions involved . Classical target cells forLPS are monocytes, macro-
phages, and endothelial cells . According to recent evidence they respond not only
to the LPS molecule itself but also to proteins associated with it (42) . IFN-y is well
known to be a strong activator of phagocytic (43) and endothelial cells (44), both
prolific producers of IL-1 . ExogenousTNF can mimick thetoxic effects ofLPS (for
reviews see references 45, 46) . Furthermore, IFN-y andTNF are known to syner-
gize in various model systems (47, 48) . Since treatment with anti-IFN-y antibody
notonly prevented the lethal response, but also blocked the induction of circulating
TNF associated with the lethal reactions, it seems logical to propose that IFN-'r con-
stitutes a pathway by which LPS sensitizes animals to subsequent production and
action ofTHEA quite similar situationhas been observed in experimental cerebral
malaria, in which anti-IFN-y treatment also prevents mortality and the associated
TNF production (49) .
Whereas interaction with TNF seems themost plausible explanation for the sen-
sitizing effect exerted by IFN-y, there are other factors such as proteases, pros-
taglandins, leukotrienes, reactive oxygen and vasoactive peptides, all ofwhich can1866
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contribute to the toxic manifestations in animals exposed to LPS . The production
and action of these factors may also be regulated by IFN--y . It is possible therefore
that further research will reveal additional in vivo pathways by which IFN-y inter-
venes in LPS pathology. In particular, it will be intriguing to find outwhat role should
be assigned to LPS-associated proteins (42) in the induction ofIFN-y as well as in
the higher sensitivity to LPS of the IFN-y-exposed host .
In clinical practice, LPS-induced shock is encountered as a complication in cases
of Gram-negative sepsis . Thefrequency ofthis conditionhasbeen steadily increasing,
due to the ever-increasing number of medical interventions that compromise host
defenses, such as aggressive chemotherapy forcancer or organ transplantations (50) .
Furthermore, improved treatment for severely burned patients, has also led to an
increasing number of such patients being at risk for Gram-negative sepsis . There
is currentlyno effectivetreatment or prophylaxis for theoccurrence ofshock in these
patients . The demonstration that cytokines such as TNF and IFN-y are pivotal in
the pathogenesis opens new perspectives for the development of novel strategies to
prevent these complications .
Summary
The involvement of cytokines in the pathogenesis of a generalized, Shwartzman-
like lethal inflammatory response to bacterial lipopolysaccharides (LPS) was studied
by testing the ability of cytokines or neutralizing anticytokine antibodies to modify
the course of the syndrome . The reaction was elicitable in non-SPF NMRI mice
by two consecutive injections of S . marcescens LPS : a first injection in the footpad,
followed after 24 h by an intravenous dose ; the size and route of the preparatory
LPS dose were found to be critical . Treatment with mAbs against IFN-y was found
to completely prevent the reaction . Treatment with IFN-y on the other hand, ren-
dered the mice more sensitive to elicitation of the reaction . In contrast, systemic
administration of IFN-cdo exerted a desensitizing effect .
Therole of endogenous cytokines in the pathogenesis ofthis generalized Shwartzman
reaction was also documented by a study of the cytokine levels in the serum of the
mice . In comparisons between mice given lethal andnonlethal induction schedules,
a good correlation was found between mortality rates and height of IFN or TNF
levels, but no correlation was seen with IL-6 levels . Also, inmice that were protected
by anti-IFN-y antibody, serum IFN andTNFwere undetectable, whereas IL-6 levels
were as high as in unprotected mice .
These data provideevidence that among the cytokines that govern the inflamma-
tory response to LPS, endogenous IFN-y occupies a key position . These findings
therefore also open perspectives for clinical application of IFN-y antagonists.
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